Comparative evaluation of fecal fat excretion induced by orlistat and chitosan

被引:50
作者
Guerciolini, R
Radu-Radulescu, L
Boldrin, M
Dallas, J
Moore, R
机构
[1] Hoffmann La Roche Inc, Nutley, NJ 07110 USA
[2] F Hoffmann La Roche, Palo Alto, CA USA
[3] F Hoffmann La Roche & Co Ltd, CH-4002 Basel, Switzerland
[4] F Hoffmann La Roche, Welwyn Garden City, Herts, England
来源
OBESITY RESEARCH | 2001年 / 9卷 / 06期
关键词
orlistat; lipase inhibition; chitosan; fecal fat;
D O I
10.1038/oby.2001.47
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To compare the effects of chitosan and orlistat on fecal fat excretion. Research Methods and Procedure: A randomized, open-label, two-period sequential design study was used. A total of 12 healthy adult volunteers within 20% of their ideal body weight entered a 7-day run-in diet period before being randomized to orlistat (120 mg) or chitosan (890 mg) three times daily for 7 days. Subjects then crossed over treatment regimens for an additional 7-day period. Subjects followed a standardized diet (2500 kcal/d, 30% as fat) for the entire 21-day study. Feces were collected on days 4 to 7 of the run-in period (baseline) and during the two treatment periods. Mean daily fecal fat excretion was measured at baseline and during each treatment regimen. Results: Mean baseline fecal fat excretion for all subjects was 1.36 +/- 0.45 g/d. During orlistat treatment, mean fecal fat excretion significantly increased from baseline (+16.13 +/- 7.27 g/d; p < 0.001). No significant effect was observed with chitosan (+0.27 +/- 1.02 g/d; p = 0.379). Fecal fat excretion was significantly greater with orlistat than-with chitosan (p < 0.001; 95% confidence intervals: 11.73; 20.00 g/d). Discussion: This study provides additional evidence of the inhibitory effect of orlistat on dietary fat absorption. Chitosan, however, has no effect on fecal fat excretion.
引用
收藏
页码:364 / 367
页数:4
相关论文
共 23 条
[11]   SOLUBILITY AND STRUCTURE OF N-CARBOXYMETHYLCHITOSAN [J].
MUZZARELLI, RAA ;
ILARI, P ;
PETRARULO, M .
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 1994, 16 (04) :177-180
[12]   Dietary chitosan inhibits hypercholesterolaemia and atherogenesis in the apolipoprotein E-deficient mouse model of atherosclerosis [J].
Ormrod, DJ ;
Holmes, CC ;
Miller, TE .
ATHEROSCLEROSIS, 1998, 138 (02) :329-334
[13]   Randomized, double-blind trial of chitosan for body weight reduction [J].
Pittler, MH ;
Abbot, NC ;
Harkness, EF ;
Ernst, E .
EUROPEAN JOURNAL OF CLINICAL NUTRITION, 1999, 53 (05) :379-381
[14]   Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity [J].
Rössner, S ;
Sjöström, L ;
Noack, R ;
Meinders, AE ;
Noseda, G .
OBESITY RESEARCH, 2000, 8 (01) :49-61
[15]   A descriptive study of weight loss maintenance:: 6 and 15 year follow-up of initially overweight adults [J].
Sarlio-Lähteenkorva, S ;
Rissanen, A ;
Kaprio, J .
INTERNATIONAL JOURNAL OF OBESITY, 2000, 24 (01) :116-125
[16]   Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients [J].
Sjöström, L ;
Rissanen, A ;
Andersen, T ;
Boldrin, M ;
Golay, A ;
Koppeschaar, HPF ;
Krempf, M .
LANCET, 1998, 352 (9123) :167-172
[17]   A NOVEL USE OF CHITOSAN AS A HYPOCHOLESTEROLEMIC AGENT IN RATS [J].
SUGANO, M ;
FUJIKAWA, T ;
HIRATSUJI, Y ;
NAKASHIMA, K ;
FUKUDA, N ;
HASEGAWA, Y .
AMERICAN JOURNAL OF CLINICAL NUTRITION, 1980, 33 (04) :787-793
[18]  
VANDEKAMER JH, 1949, J BIOL CHEM, V177, P347
[19]  
Veneroni G, 1996, CHITIN ENZYMOLOGY, P63
[20]  
Ventura P, 1996, CHITIN ENZYMOLOGY, V2, P55